ArticleFrontiers in immunology2025
Proliferative glomerulonephritis with monoclonal immunoglobulin deposition coexisting with ANCA-associated glomerulonephritis: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PR3-ANCA-Associated Vasculitis in IgGκ MGUS: A Fatal Case of Rapidly Progressive Glomerulonephritis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID) is a rare variant of monoclonal gammopathy of renal significance (MGRS). Although the pathogenesis of PGNMID is not yet fully understood, it is currently hypothesized to originate from the intraglomerular deposition of pathogenic monoclonal immunoglobulins secreted by B cells or plasma cells. Typically, these deposits exhibit light chain restriction, with κ light chains being the most prevalent. Therapeutic strategies for PGNMID are based on targeting the abnormal or potential clone. However, the combination of corticosteroids and cyclophosphamide has also been reported. In this report, we describe an extremely rare clinical case of λ light chain type PGNMID occurring simultaneously with ANCA-associated glomerulonephritis. After treatment with the combination of corticosteroids and cyclophosphamide, the patient demonstrated reduced proteinuria and stable renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.